Myeloblasts derived from the peripheral blood of a patient with acute myelogenous leukemia (ORL47) were found to represent the malignant counterpart of the newly elucidated monocyte-dendritic cell colony-forming unit (mono-DC-CFUI. The specific cytokine conditions required to achieve intermediate and terminal maturation of DCs and monocytes from these progenitors were defined. With tumor necrosis factor (TNF) + granulocyte-macrophage colony-stimulating factor (GM-CSF) + stem cell factor treatment numerous colony-like clusters developed. In contrast with normal DC development, further advancement of mono-DC-CFU and terminal DC maturation from the leukemic cells were dependent on the addition of interleukin-6. Functional ECENT ADVANCES in stem cell biology have had tremendous impact on our understanding of the pathophysiology of hematologic malignancie~."~ Both normal and malignant hematologic differentiation are multistep processes governed by cytokines. Distinct cytokines, acting alone or in synergy, initiate lineage commitment from a common multipotential progenitor cell, subsequently produce intermediate progenitors, and ultimately generate endstage p r~g e n y .~.~ Thus, the fate of specialized progeny is not only dependent on the immediate external environment, but also on the responsive state of the precursor cell.'" Various malignant counterparts exist which correspond to particular stages of the lymphoid, myeloid, erythroid, and megakaryocytic ~e r i e s , "~ suggesting that clonal aberrations may occur at different levels of hematologic development.
ECENT ADVANCES in stem cell biology have had tremendous impact on our understanding of the pathophysiology of hematologic malignancie~."~ Both normal and malignant hematologic differentiation are multistep processes governed by cytokines. Distinct cytokines, acting alone or in synergy, initiate lineage commitment from a common multipotential progenitor cell, subsequently produce intermediate progenitors, and ultimately generate endstage p r~g e n y .~.~ Thus, the fate of specialized progeny is not only dependent on the immediate external environment, but also on the responsive state of the precursor cell.'" Various malignant counterparts exist which correspond to particular stages of the lymphoid, myeloid, erythroid, and megakaryocytic ~e r i e s , "~ suggesting that clonal aberrations may occur at different levels of hematologic development.
In general terms, myeloid leukemias may be defined as hematologic malignancies frozen at early stages of myeloid differentiation. As with other clonal abnormalities, self renewal in acute leukemias is favored over differentiation, although limited normal differentiation events may occur in vivo.','" In vitro studies have shown that heterogeneity in the proliferative and maturational response of myeloid leukemias is caused by arrest at different stages of hematopoietic differentiation."'" The current French-American-British (FAB) classification system for acute myeloid leukemias (AMLs) considers this heterogeneity and recognizes eight subgroups (MO-M7).".'* Further heterogeneity has been described within subgroups, such as M2, to include distinct chromosomal translocations, ie, t(8;21)." Notwithstanding, leukemic clones regularly fall outside these schemes, sug-and phenotypic analysis showed that the capacity to differentiate was maintained fully in the DC compartment, but only partially in the monocyte compartment, as judged by the lack of CD14 surface expression. Cells found at intermediate stages of DC development were potent stimulators of a mixed leukocyte reaction, a function usually attributed to mature DCs. As previously shown for normal DC development, antibodies to TNFa and GM-CSF blocked proliferative responses and DC growth. The importance of these observations in the classification of leukemias, normal DC development, and potential clinical strategies is discussed. gesting that normal equivalents of particular clones remain unidentified or unclassified. The known AML subgroups that are not defined by FAB are undifferentiated acute leukemia, MO, mixed lineage acute leukemia, and hypocellular AML."
Cells belonging to the dendritic cell (DC) series are distinct myeloid elements that have been recognized for some time as crucial in managing the presentation of antigen to immune cells.'"'6 There have been several accounts of malignancies exhibiting features of DCS.'~-'* However, there has been no identification of the malignant progenitor in any of these diseases and there is currently no way of classifying DC malignancies.** Some investigators have argued that a proportion of monocytic leukemias are precursors of Langerhans cells (LC, the skin component of the DC series) in LC histiocytosis (LCH)," but the relationship between the monocytic and the LC pathway was not described.
We and others have recently traced the normal developmental pathway of DCs and have shown that DCs and monocytes develop simultaneously under the influence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor (TNF) from a common progenitor cell unit that has been termed the monocyte-DC colony-forming unit (mono-DC-CFU).23'2h In addition, we have shown that stem cell factor (SCF) in combination with TNF and GM-CSF optimizes the development of DCs from these progenitor cells (Santiago-Schwarz F, manuscript in preparation). In this study, we have exploited observations of normal DC development to recognize a malignant counterpart of the mono-DC-CFU in an AML that we designate ORL47. We show that the leukemic cells differentiate along the DC pathway and define the specific cytokine combinations required to achieve seemingly normal differentiation events. The term myelodendritic leukemia is suggested to describe this malignancy.
MATERIALS AND METHODS
Cluss$cation of the myeloid leukemia and clinical course. The leukemic cells analyzed were obtained after informed consent from a 38-year-old white woman with refractory AML. The patient presented 4 months earlier with fevers and diffuse inflammation of the left breast and rectum. Myeloblasts were detected on the peripheral smear, a bone marrow (BM) aspiration, biopsy, and a needle aspiration biopsy of the breast were performed, and the diagnosis of AML, FAB,M2, with granulocytic sarcoma was made according to standard morphologic and cytochemical criteria"." by two independent reviewers. The BM differential (the Wright stain is shown in Fig I ) showed 47% myeloblasts, 5% promyelocytes, 2% myelocytes, X% metamyelocytes, 25% polymorphonuclear cells, 6% lymphocytes, 2% plasma cells, and S% normoblasts. Sudan Black staining was strongly positive in 10% of the cells, weakly positive in 66%. and negative in 24%. Myeloperoxidase staining was strongly positive in 11%. weakly positive in 62%. and negative in 27%. a-naphthyl acetate esterase staining was strongly positive in 3%. weakly positive in 17%. and negative in 80%. Combined esterase staining showed mostly chloroacetate esterase positive (76%), and a-naphthyl acetate esterase negative (78%). lmmunophenotypic analysis of the BM aspirate (performed at the Roswell Park Memorial Institute, Buffalo. NY) showed two separate populations: a more primitive population was CD33'CD13' (20%). whereas a more differentiated one expressed only CD13 (57%). The single expression of the T-cell markers CD2. CD3, CD7, and CD8 was less than 3%. Total CD4 expression was 32%. and, of these, only 1.13% were CD3'CD4'CDX-M and 0.16% were CD3'CD4'CDX'. B-cell marker expression, including CDIO, CD19. and CD20 was less than 2%. and natural killer (NK) (CD16, CDS6) cell-associated marker expression was less than 1%. Total CD34, HLA-DR. CD1 I b and CD14 expression was 33%, 17%. 62%. and 3.496, respectively.
Karyotypic analyses performed on two distinct occasions were normal. Needle biopsy of the breast yielded only scant myeloblasts and neutrophils. No bacteria were identified on the smears, and microbiologic cultures were negative.
The patient was treated with empiric broad-spectrum antibiotics that included anaerobic coverage for the presumed infection or superinfection of the breast and rectum. The leukemia was refractory to two courses of chemotherapy with cytosine arabinoside and daunorubicin. Remission was achieved with m-Amsa (amsacrine: National Cancer Institute, Bethesda, MD) and high-dose cytosine arabinoside. Four months later, the patient relapsed and died with refractory disease. Immediately before her death, she developed a granulocytic sarcoma of the tongue and required intubation. Needle aspiration of the tongue showed scant myeloblasts and neutrophils.
Enrichment of leukemic hlusts. Thirty milliliters of peripheral blood (PR) wds obtained by venipuncture in accordance with institutional guidelines. At the time of collection (4 months after diagnosis), the patient had not received chemotherapy for 10 weeks. and the PB white blood cell (WBC) count was 59.WO/mL. WBCs were isolated from the buffy coat after centrifugation and stored in liquid nitrogen in 10% dimethylsulfoxide/90% growth medium until needed. After thawing, leukemic cells (designated ORL47) were adjusted to -4 X 10' cellslrnL in RPM1 1 6 4 0 medium (GIBCO, Grand Island, NY) containing 10% fetal bovine serum (FBS; GIBCO), 2 mmol/L glutamine, S0 IUlmL penicillin. S0 pg/mL streptomycin (FBSIRPMI) and placed in a S% CO: humidified incubator at 37°C for 3 to S days. Nonadherent cells were then removed from culture, washed in RPM1 1640. and adjusted to 0.5 to 1 X 10' cells/ mL. The blast cell content after this preincubation period was greater than 80%: lymphocyte content was less than S%, and polymorphonuclear leukocyte (PMN) content was less than 10%. as determined by Wright-stain analysis and flow cytometry. Cyrokinc rremncnr. Recombinant cytokines were added to the leukemic blasts, either alone or in combination, and included TNFa (Knoll Pharmaceuticals, Whippdny, NJ) at a final concentration of S00 UlmL; GM-CSF (Genzyme, Boston, MA) at a final concentration of I O 0 UImL; SCF (Cenzyme) at a final concentration of S0 ng/mL; and interleukin-6 (IL-6: Genzyme) at a concentration of 1 0 0 UImL. The concentration for each cytokine was determined after dose-response analysis as previously described and is optimal for achieving DC development from normal stem cells." Mouse antihuman GM-CSF monoclonal antibody and antihuman TNFa polyclonal (Genzyme) were used at 10 pgImL. The optimal doses of these antibodies and the effects of nonspecific controls were described in an earlier study.'' Endotoxin levels in these cultures were controlled as previously described."." Culture vessels consisted of 24-well tissue-culture plates and two-well chamber slides (plastic Lab-Tek chamber slides;
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Nunc, Naperville, IL). The leukemic cell lines HL60 and U937 and PB cells from another leukemic patient (ORL49,MS) were cultured at 2 to 3 X IO5 cellslmL in parallel fashion. Prolifprafiw crssessmcnt of crrlrurecl cells. Growth and viability were assessed by the uptake of tritiated thymidine and by hemacytometer-assisted cell counts (Improved Neubauer: Fisher Scientific. Pittsburgh. PA). For thymidine uptake, 0.5 pCi of [ 
RESULTS
Growth of ORU7 cells. During preincubation for 3 to 5 days in FBSRPMI, most (>go%) of the nonadherent leukemic cells retained blast morphology, as assessed by Wright-stain analysis (Fig 2) . Examination by phase micros- copy showed that the majority of the cells were nonadherent and that some cells exhibited veiled cell morphology ( Fig  3A) .''.'" Occasionally. a few colony-like clusters and adherent cells with typical dendritic cell and macrophage morphology were present, but in general, differentiation events in cultures containing FBSRPMI were infrequent. The lack of differentiation events coupled with good viability (>S%), the presence of numerous mitotic figures (Fig 2) . and a growth response measured by [>H]-thymidine uptake (mean, 2,000 cpm; n = 4) in these short-term blast cultures indicated that ORL47 produces autocrine growth factors that favor self-renewal over differentiation.'."' Notwithstanding, even with fresh media supplementation, the viability and growth response of these cultures began to decrease after S days. Growth in pooled AB normal human serum (NHS)/RPMI was also tested and yielded similar results (data not shown).
Diferentiation and proliferative events associated with cytokine treotment.
Normally. DC components represent less than 1% of PB.""" Because of the enhanced presence of veiled cells and adherent DC in the leukemic FBSlRPMl cultures, we compared the developmental response of ORL47 leukemic blasts with cytokine combinations that have been shown by us and others to favor DC development.""" As soon as 24 hours after cytokine treatment, changes in proliferation and maturational responses were noted. With respect to morphologic changes, GM-CSF treatment alone increased the number of processes found on the veiled cells and provoked the development of a few nonadherent CFU-like clusters (Fig 3B) . Although the combination of TNF with GM-CSF increased the number of CFU-like clusters (Fig K ) , these remained nonadherent, and few mature DC progeny were noted. With SCF + TNF + GM-CSF treatment, the number of nonadherent clusters was increased even further, but again without the development of mature DC progeny ( Fig  3D) . Interestingly, the addition of IL-6, which has been previously shown to induce the development of certain leukemic cells,"~'* resulted in the terminal differentiation of DCs. By 24 hours of TNF + GM-CSF + SCF + IL-6 treatment, numerous adherent CFU-like clusters were present in the cultures, along with noncolony-associated adherent DCs (Fig 3E) . Morphologically, these CFU-like clusters were identical to the monocyte-DC-CFU derived from normal cord blood or adult PB (Fig 4) .".'4.29 Treatment of similarly prepared mononuclear cells from normals yielded less than 1% DC progeny (data not shown).
In Table I and Fig S, we compare the proliferative events associated with ORL47 leukemic blasts treated with cytokines with culture in FBSRPMI alone. As represented in Table I , the largest increases in absolute cell counts (2.6-fold) were induced by TNF + GM-CSF + SCF treatment.
These were followed in declining order by TNF + GM-CSF 028; Fig 5) . Quantitative analysis at 72 hours by phase microscopy also showed only three mono-DC-CFU-like clusters in FBSRPMI cultures as The number of cells/mL in the ORL47 cultures was determined with a hemacytometer 24 hours after treatment. Viability was measured by Trypan blue exclusion.
Growth response relative to FBS cultures.
t Anti-TNF and Anti-GM-CSF were added together with TNF + GM-CSF, as described in the text. HL-60 conditioned media was used at a final concentration of 50% in RPMI-1640 culture medium. Results were obtained from a single experiment.
* Growth response relative to TNF + GM-CSF cultures. showed significant increases in proliferation ( P = .028). Results represent the mean of three separate experiments. In one control experiment, 10% NHS was used instead of 10% FBS. As discussed in the text, these two conditions were comparable.
compared with more than 300 mono-DC-CFU-like clusters in TNF + GM-CSF + SCF cultures.
Because conditioned medium (CM) from the leukemic cell line HL60 is enriched in hematopoietically active cytokines,3" we tested the development of ORL47 in the presence of HL60 CM. The absolute cell number was increased above FBS/RPMI cultures with HL60 CM ( Table 1 ) . but these events were not associated with DC development. as assessed by phase microscopy. The addition of IL-6 to HL60 CM also failed to induce DC development. Subsequent studies showed that neither HL60 or U937 leukemic cell lines or fresh leukemic cells from another patient (ORL49) were induced to differentiate along the DC pathway with any combination of cytokines tested (data not shown).
Differential analysis related to DC development. TO help ascertain the position of the ORL47 leukemia in the myeloid pathway, the proportion of cells which differentiate into PMN was determined. Under all the conditions examined, including treatment with GM-CSF alone, less than 1 1 % PMN cells developed in the cultures ( Table 2) . This is in contrast with the treatment of normal CD34' progenitor cells with GM-CSF, which produces -30% PMN progeny." Furthermore, unlike normal CD34' cell cultures treated with TNF + GM-CSF and anti-TNF antibodie~,'~ the addition of For personal use only. on October 27, 2017. by guest www.bloodjournal.org From anti-TNF to TNF + GM-CSF leukemic cultures (described below) did not produce a shift from mononuclear cell (MNC) to PMN progeny. These results indicate that the clonal DCmonocyte progenitor cell unit in O m 4 7 is at a post-CFU-GM stage.
Effects of anti-TNF and anti-GM-CSF antibodies on leukemic DC development. As previously described by us for normal DC differentiation, antibodies to TNF and GM-CSF inhibited leukemic DC de~elopment.'~ In these experiments anti-TNF or anti-GM-CSF was added together with TNF + GM-CSF at the onset of the culture period. As depicted in Fig 3F, anti-TNF greatly reduced colony growth. The absolute cell content was decreased by -30% and -45% for anti-TNF and anti-GM-CSF, respectively, as compared with cultures treated with TNF + GM-CSF (Table 1) . Thymidine uptake analysis also showed that addition of either antibody decreased proliferation (data not shown). Other investigators have shown that similar antibody treatment blocks proliferative responses in different leukemia^,^' in support of our observations. NSE and phagocytic activity associated with DC and monocyte-macrophage development from ORL47 leukemic cells. Leukemic blasts treated with TNF + GM-CSF + SCF + IL-6 were stained in situ for NSE and phagocytic activity. As expected, there was no NSE or phagocytic activity in either colony associated or free DCs (Fig 6, A and  B) .*' In contrast, monocyte-macrophages developing simultaneously from mono-DC-CFU exhibited both NSE activity and the capacity to ingest Ig-coated magnetic beads. In situ immunofluorescence analysis also showed that while expressing class I1 MHC antigens on their surface, these DCs did not express monocyte-macrophage-associated CD14 antigens (data not shown). Unexpectedly, free and colony-associated monocyte-macrophages were also negative for CD 14, suggesting a leukemic defect involving the CD14 protein.
The capacity of ORL47 cells to induce a mixed leukocyte reaction (MLR). The MLR stimulatory potential of ORL47 leukemic cells cultured with TNF + GM-CSF + SCF, TNF + GM-CSF + SCF + IL-6, or FBSRPMI alone was explored (Fig 7) . At stimulator to responder cell ratios of 0.2: 1, cultures containing stimulator cells treated with either TNF
exhibited an equal proliferative capacity that was approximately threefold greater than that exhibited by cukures containing FBS/RPMI alone. The capacity to produce a potent MLR in these cultures was retained even at stimulatorxesponder ratios as low as 0.06: 1, which is consistent with a DC-mediated T-cell response.14"6332 Because there were few mature DCs in TNF + GM-CSF + SCF cultures, these results indicate that cells found at intermediate stages of DC development are capable of inducing potent MLRs.
DISCUSSION
We have described a malignant counterpart of the mono-DC-CFU in an AML and the multistep induction of mature progeny from these blasts. Differentiation was under tight cytokine control, with both DCs and monocytes arising from the leukemic cells. Although proliferative events and partial differentiation were achieved with TNF + GM-CSF and TNF + GM-CSF + SCF (Table 1, Figs 3 and 5) , subsequent development of mono-DC-CFU and terminal maturation of DCs was dependent on the addition of IL-6 (Figs 3 and 6) . These results are in contrast with those previously published for the development of DCs from normal CD34+ stem cells that require only synergy between TNF and GM-CSF to achieve a large yield of DC p r~g e n y . '~.~~ Because we were able to maintain short-term growth of ORL47 cells in the absence of stromal elements and exogenous cytokines, and achieve in vitro differentiation with the specified cytokines, it appears that O W 7 represents a differentiation positive leukemia that produces autocrine factors that favor self-renewal over differentiation?." Because GM-CSF increased the growth response of leukemic cells with few differentiation events ( Table 1 , Fig 3B) and has previously been described to promote self-renewal in most AML,33,34 it is possible that GM-CSF is also involved in the self-renewal of ORL47.
Morphologically, development of the mono-DC progenitor cells treated with TNF + GM-CSF + SCF + IL-6 into colonies containing DCs and monocytes (Figs 3E and 6) was identical to that previously reported for CD34+ stem cells treated with either TNF + GM-CSFZ3 (Fig 3) or TNF + GM-CSF + SCF (Santiago-Schwarz F, in preparation). However, with respect to temporal kinetics, the development of mono-DC colonies from leukemic cells occurred much more rapidly than from normal CD34+ stem cells (24 hours v 5 days), suggesting that additional maturational steps were required in the CD34' progenitor cell compartment. Leukemia-derived mature DCs exhibited phenotypic and functional features of normal stem cell-derived DCs including the lack of NSE and phagocytic activity (Fig 6) , the lack of CD14 expression, the presence of class I1 MHC antigens (data not shown), and the capacity to induce a potent MLR (Fig 7) .23- 27 In contrast, normal differentiation was maintained only partially in the monocytic compartment, as assessed by the presence of NSE and phagocytic activity (Fig 6) , and the absence of surface CD14 antigens (data not shown).
Although leukemic blasts treated with TNF + GM-CSF + SCF did not undergo terminal maturation into DCs, these cultures exhibited a potent MLR stimulatory capacity, equal to that of cultures containing terminally differentiated DCs (TNF + GM-CSF + SCF + IL-6). This observation indicates that cells found at intermediate stages of DC differentiation are functionally competent. In support of this, Thomas et a1 have recently shown that cultured CD33'CD13+ DC precursors are effective stimulators of a MLR before they differentiate into mature DC. 35 The dependency of ORL47 on exogenous IL-6 may not represent a unique leukemic event, but an example of the regulatory role of secondary cytokines in myelopoiesis. IL-6 has been shown to be an important secondary cytokine during normal GM-CSF-induced monocyt~poiesis.~~ Because mono-mQs arising during development produced IL-6, a developmentally active cytokine loop involving IL-6 was suggested in this report. In other reports, IL-6 was found to be a secondary cytokine stimulated by TNFa that supported the development of CFU from AML blast^.^' Some AML blasts categorized as FAB M1-M4 do not produce ILFor personal use only. on October 27, 2017. by guest www.bloodjournal.org From 6, but express L-6 receptors:' indicating that these leukemias are susceptible to the effects of L-6. Although we did not determine the expression of L-6 receptors on ORL47, their expression would be expected because O m 4 7 exhibited an FAB M2 phenotype and responded to L-6. Based on these data, we speculate that the dependency of O m 4 7 blasts on exogenous L-6 reflects the lack of endogenous secondary L-6 production by a population of cells (probably mono-mas), and that this cytokine might be produced as a secondary cytokine during mono-DC development from normal CD34+ progenitor cells. Some investigators have
proposed that L-6 may sustain leukemic blast development by preventing cell death by apoptosis." Because L-6 seemed to promote the release of DC from the colonies as well as DC adherence, it may be that the effect is also adhesion molecule associated.
The inability to produce PMN progeny with GM-CSF (Table 2) , and the lack of a MNC to a PMN cell deviation with anti-TNF treatment indicate that the clonal component in O W 7 is at a distinct post-GM-CFU stage, specifically primed for DC and monocyte-macrophage development. A CD33+CDl3+ DC precursor has recently been described in normal PB that may be the normal equivalent of ORL47." We have also described an analogous post-CFU-GM, mono-DC progenitor in cord blood that resembles O m 4 7 (Santiago-Schwarz F, in preparation). Our attempts to induce DC development from the HL60 (GM-CFU) and U937 (M-CFU) leukemic cell lines and from leukemic blasts isolated from a patient with AMLS failed, further supporting the concept that O m 4 7 is a distinct leukemic DC progenitor cell unit that is at the post-GM-CFU stage.
It might be argued that some of the differentiation events we describe are caused by the development of normal, and not leukemic progenitors. Whereas it is possible that nonleukemic progenitors are initially contained in our leukemic blast cell-enriched fractions, there are several arguments against their development. Foremost, normal progenitor cells die quickly (within 72 hours) in culture if not provided with the appropriate exogenous c y t~k i n e s ,~~. " ,~~ and thus, would not have survived the 3-to 5-day preincubation period in FBS/RPMI. If the leukemic blasts were producing hematopoietically active cytokines such as GM-CSF, and normal progenitors were present, differentiation events should have occurred in FBSRPMI cultures. Instead, differentiation events were virtually absent in these cultures. Finally, because PMN development would have been supported by GM-CSF, the lack of PMN progeny also argues against the presence of normal progenitors such as GM-CFLJ and GEMM-CFLJ.
In addition to lending further insight into the classification of leukemias and the DC pathway, these observations help clarify the relationship between LCH abnormalities and malignancies. Although there is a growing number of reports describing associations between AML and LCH, the origin of the LC component has remained u r~d e f i n e d . '~,~' ,~~,~~ It has been suggested that the histiocyte element in LCH arises either from a monocyte or from an as yet unidentified progenitor.'8.20*2' Our results clearly show that an AML clone exists that is a common mono-DC progenitor. Conceivably, in AML with associated LCH, mono-DC leukemic progenitor cells could infiltrate tissues in response to chemotactic agents and inflammatory cytokines, as do DC components during normal infiltrati~n.'~"~ Depending on the tissue and the availability of cytokines such as IL-6, TNF, and GM-CSF, further maturation of the leukemic blasts into DC and monocyte-macrophages may ensue. Thus, in AML with as-1 3061 sociated LCH, histiocytes may not represent the malignant element, but the local accumulation of a differentiated product of leukemic blasts. The triggering events for homing of the leukemic cells may involve a local insult that leads to the production of cytokines that induce DC development. The propensity to develop infiltrating lesions of the breast, rectum, and tongue allows the speculation that the above mechanism may have been operative in the patient we describe.
The frequency of DC-related leukemias is not known. Because monocyte-macrophage progeny can be achieved from three ontogenically different routes, (GM-CFLJ, M-CFU, and mono-DC-Cm), it is likely that aberrations in the monocytic pathway are a more common form of AML. Some investigators have argued that monocytic leukemias may be precursors of LC." Other investigators have described an unusual AML in which DC-like elements developed from AML cells cultured in T-cell-conditioned medium." Like ORL47, this AML was unusually aggressive. Although the progenitor and specific cytokine growth requirements were not identified, the phenotypic and functional features of progeny derived from this leukemia were similar to ORL47 and indicate that it may be its equivalent.
By using an in vitro approach similar to the one used in this study, other leukemias can be easily screened for DC development. This type of developmental analysis coupled with antigen profiles and clinical data should provide a basis for accurately including myelodendritic leukemias in leukemic classification schemes. Because of the strict requirements for achieving DC differentiation, any clinical strategy aimed at targeting such leukemias should consider the specific growth requirements of the DC pathway. 
